(Q33385649)

English

The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo (English)

1 reference

Europe PubMed Central

26 July 2017

0 references

oligosaccharide

1 reference

based on heuristic

inferred from title

tumor angiogenesis

1 reference

based on heuristic

inferred from title

author name string

Jingui Ma

1

1 reference

Europe PubMed Central

26 July 2017

Xianliang Xin

2

1 reference

Europe PubMed Central

26 July 2017

Linghua Meng

3

1 reference

Europe PubMed Central

26 July 2017

Linjiang Tong

4

1 reference

Europe PubMed Central

26 July 2017

Liping Lin

5

1 reference

Europe PubMed Central

26 July 2017

Meiyu Geng

6

1 reference

Europe PubMed Central

26 July 2017

Jian Ding

7

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

20 November 2008

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

3

1 reference

Europe PubMed Central

26 July 2017

11

1 reference

Europe PubMed Central

26 July 2017

e3774

1 reference

Europe PubMed Central

26 July 2017

copyright license

Creative Commons Attribution 4.0 International

20 November 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Establishment of the active catalytic domain of human PDGFRbeta tyrosine kinase-based ELISA assay for inhibitor screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Targeted cancer therapy: promise and reality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Angiogenesis: an organizing principle for drug discovery?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Sorafenib for the treatment of advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Angiogenesis as a therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

11,11'-dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Current methods for assaying angiogenesis in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Imatinib as a paradigm of targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Tyrosine kinase inhibitors in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Targeting HER1/EGFR: a molecular approach to cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Smart drugs: tyrosine kinase inhibitors in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Tyrosine kinase inhibitors: from rational design to clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Mechanism of action of anti-HER2 monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Oncogenic kinase signalling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Structure-based strategies for drug design and discovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

21 June 2018

Gefitinib--a novel targeted approach to treating cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003774

21 January 2018

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003774

21 January 2018

Research on resistance to cancer drug Gleevec

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003774

21 January 2018

Treating cancer's kinase 'addiction'.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003774

21 January 2018

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003774

21 January 2018

Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003774

21 January 2018

Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits T cell apoptosis by combating oxidative damage of mitochondria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582481

31 October 2018

Description of an enzyme-linked immunosorbent assay for the detection of protein tyrosine kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting tyrosine kinases in cancer: the second wave

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oligosaccharides as anti-angiogenic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0003774

1 reference

Europe PubMed Central

26 July 2017

2008PLoSO...3.3774M

0 references

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33385649&oldid=1871355001"